Top Trends Driving Innovation and Change in the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market: Advancements In Cell And Gene Therapy Manufacturing
Discover trends, market shifts, and competitive outlooks for the cell and gene therapy contract development and manufacturing organization (cdmo) industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
What Is the Current and Projected Market Size of the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Through 2034?
The market size of the contract development and manufacturing organization (CDMO) for cell and gene therapy has noticeably expanded over the past few years. It is projected to rise from $5.41 billion in 2024 to $6.94 billion in 2025, presenting a compound annual growth rate (CAGR) of 28.2%. Factors like advancements in technology, regulatory environment favoring its growth, higher investment, a higher incidence of genetic disorders, and an upsurge in strategic collaborations have contributed to the growth during the historical period.
The market for contract development and manufacturing organizations (CDMO) in cell and gene therapy is anticipated to witness substantial expansion in the impending years. The market’s worth is predicted to soar to $18.54 billion in 2029, with a compound annual growth rate (CAGR) of 27.8%. This substantial growth in the forecasted period can be ascribed to numerous factors including the extension of therapeutic applications, developments in regulations, amplified investments, technological advancements, and international cooperation. In the forecast period, key trends to expect encompass an escalating demand for individualized therapies, development in automation and digitalization, broadening of manufacturing capabilities, emergence of innovative delivery systems, and an intensified emphasis on sustainability and ecological impact.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15753&type=smp
What External and Internal Drivers Are Contributing to the Growth of the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?
The escalating incidence of cancer is predicted to spur the expansion of the cell and gene therapy contract development and manufacturing organization (CDMO) market. Defined as a cluster of illnesses marked by uncontrolled proliferation and distribution of abnormal cells within the body, cancer’s growing incidence can be attributed to factors such as an aging demographic, lifestyle modifications, exposure to harmful environments, and more sophisticated detection techniques. CDMOs play an instrumental role in curtailing the incidence of cancer by creating and producing targeted, innovative treatments that amplify efficacy and improve patient results. Macmillan Cancer Support, a UK-based charity, projected in October 2022 that the number of individuals in the UK living with cancer is anticipated to surge from 3 million in 2022 to 3.5 million by 2025, 4 million by 2030, and ultimately reach 5.3 million by 2040. Thus, the escalating incidence of cancer propels expansion in the cell and gene therapy contract development and manufacturing organization (CDMO) market.
What Segment Types Define the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Structure?
The cell and gene therapy contract development and manufacturing organization (CDMO) market covered in this report is segmented –
1) By Product Type: Gene Therapy, Gene-Modified Cell Therapy, Cell Therapy
2) By Phase: Phase 1, Phase 2, Phase 3, Phase 4
3) By Indication: Oncology, Infectious Diseases, Neurological Disorders, Rare Diseases, Other Indications
Subsegments:
1) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Gene Therapy, Plasmid DNA-Based Gene Therapy
2) By Gene-Modified Cell Therapy: CAR-T Cell Therapy, TCR-T Cell Therapy, NK Cell Therapy
3) By Cell Therapy: Stem Cell Therapy, Progenitor Cell Therapy, Immune Cell Therapy
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=15753&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?
North America was the largest region in the cell and gene therapy contract development and manufacturing organization (CDMO) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy contract development and manufacturing organization (CDMO) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Which Cutting-Edge Market Trends Are Expected to Drive the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market’s Growth?
Prominent corporations in the cell and gene therapy contract development and manufacturing organization (CDMO) market are aiming to enlarge their offerings using sophisticated solutions like PluriMatrix technology, to improve the scalability, productivity, and caliber of cell-based product development. PluriMatrix technology is a proprietary system designed for mass production of cell-based items. This progressive technology enables the 3D expansion of cells on a commercial level, ensuring high output and reliability via an automated, fully managed, and verified procedure. For example, Pluri, a biotech firm based in Israel, unveiled PluriCDMO, a new business sector that offers cell therapy production services as a CDMO, in January 2024. The new sector includes a good manufacturing practice (GMP) cell therapy manufacturing facility spanning 47,000 square feet. Pluri’s newly formed division provides comprehensive services right from the early preclinical phases to late-stage clinical tests and commercialization, offering process and analytical development, scale-up, validation, logistics, automation, and regulatory-approved comparability studies, according to a company announcement. The company’s state-of-the-art PluriMatrix technology is utilized in this division to provide advanced cell therapy manufacturing services.
View the full report here:
What Is the Definition of the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?
A cell and gene therapy contract development and manufacturing organization (CDMO) is a specialized company that provides services to support the development, manufacturing, and commercialization of cell-based and gene therapy products. These organizations offer services tailored to the unique needs of companies developing advanced therapies, including biopharmaceutical companies, academic institutions, and government agencies. Cell and gene therapy CDMOs play a critical role in accelerating the development and commercialization of advanced therapy products by offering specialized expertise, infrastructure, and services to support their clients’ needs from early-stage development through commercialization.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15753
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
